The stock of BridgeBio Pharma Inc. (NASDAQ:BBIO) last traded at $17.36, up 2.78% from the previous session.
Data from the available sources indicates that BridgeBio Pharma Inc. (NASDAQ:BBIO) is covered by 11 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $40.00 and a low of $18.00, we find $29.00. Given the previous closing price of $16.89, this indicates a potential upside of 71.7 percent. BBIO stock price is now 15.24% away from the 50-day moving average and 43.46% away from the 200-day moving average. The market capitalization of the company currently stands at $2.80B.
In total, 0 analysts have assigned it a hold rating, and 10 have given it a buy rating. Brokers who have rated the stock have averaged $28.60 as their price target over the next twelve months.
With the price target of $40, Evercore ISI recently initiated with Outperform rating for BridgeBio Pharma Inc. (NASDAQ: BBIO).
In other news, Kumar Neil, CEO and President sold 51,552 shares of the company’s stock on May 17. The stock was sold for $722,218 at an average price of $14.01. Upon completion of the transaction, the CEO and President now directly owns 4,813,197 shares in the company, valued at $83.56 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 17, Secretary, Treasurer & CFO STEPHENSON BRIAN C sold 24,424 shares of the business’s stock. A total of $342,168 was realized by selling the stock at an average price of $14.01. This leaves the insider owning 36,408 shares of the company worth $0.63 million. Insiders disposed of 1,493,809 shares of company stock worth roughly $25.93 million over the past 1 year. A total of 4.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BBIO stock. A new stake in BridgeBio Pharma Inc. shares was purchased by FRAZIER LIFE SCIENCES MANAGEMENT, L.P. during the first quarter worth $20,340,000. MARSHALL WACE, LLP invested $18,829,000 in shares of BBIO during the first quarter. In the first quarter, AVIDITY PARTNERS MANAGEMENT LP acquired a new stake in BridgeBio Pharma Inc. valued at approximately $17,360,000. EVENTIDE ASSET MANAGEMENT, LLC acquired a new stake in BBIO for approximately $16,339,000. IKARIAN CAPITAL, LLC purchased a new stake in BBIO valued at around $10,324,000 in the second quarter. In total, there are 257 active investors with 98.10% ownership of the company’s stock.
With an opening price of $16.79 on Monday morning, BridgeBio Pharma Inc. (NASDAQ: BBIO) set off the trading day. During the past 12 months, BridgeBio Pharma Inc. has had a low of $6.55 and a high of $19.94. The fifty day moving average price for BBIO is $15.13 and a two-hundred day moving average price translates $12.13 for the stock.
The latest earnings results from BridgeBio Pharma Inc. (NASDAQ: BBIO) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.92, missing analysts’ expectations of -$0.83 by -0.09. This compares to -$1.38 EPS in the same period last year. The company reported revenue of $1.83 million for the quarter, compared to $1.69 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.79 percent. For the current quarter, analysts expect BBIO to generate $3.33M in revenue.
BridgeBio Pharma Inc.(BBIO) Company Profile
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
